Aurobindo Pharma subsidiary, CuraTeQ expands scope of agreement signed with Orion

11 Jan 2022 , 03:00 PM

Earlier in 2020, CuraTeQ Biologics (CuraTeQ) and Orion Corporation (Orion) had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQs biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia.

Under the terms of the agreement, Orion will be responsible for commercialization of CuraTeQs biosimilar products, currently in various stages of development/filing for the partnered territories. CuraTeQ will leverage Aurobindos established commercial presence in the nine European markets, including United Kingdom, France, Germany, Spain, Italy, Portugal to commercialise the biosimilar products in these markets (non- partnered).

CuraTeQ filed its first oncology biosimilar product with the European Medicines Agency (EMA) in September 2021 and filed its second biosimilar product, also in the oncology segment on 10 January 2022.

On a consolidated basis, Aurobindo Pharmas net profit fell 13.7% to Rs 696.71 crore on 7.7% decline in net sales to Rs 5,889.93 crore in Q2 FY22 over Q2 FY21.

Shares of Aurobindo Pharma declined 2.05% to Rs 722.85 on BSE. Aurobindo Pharma headquartered at Hyderabad, India, develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients.

Powered by Capital Market – Live News